Effects of PA-1 Transcriptional Regulation on Monocyte Function

This study has been terminated.
(Investigator left institution)
Sponsor:
Collaborator:
Information provided by:
Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00512369
First received: August 3, 2007
Last updated: July 14, 2011
Last verified: July 2011
  Purpose

Researching genetic differences in people with no prior medical conditions for better understanding of cardiac diseases through genetic research.


Condition
Atherosclerosis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Angiotensin, the Vascular Endothelium, and Fibrinolysis - The Effects of PAI-1 Transcriptional Regulation on Human Monocyte Function

Resource links provided by NLM:


Further study details as provided by Vanderbilt University:

Estimated Enrollment: 125
Study Start Date: March 2006
Study Completion Date: July 2011
Detailed Description:

The discovery and subsequent application of small interfering RNA (siRNA) methods to achieve individual gene silencing in mammalian cells is a robust method that is well-described and validated in mammalian cell culture systems. We will apply this technique to achieve post-transcriptional "silencing" of PAI-1 in monocytes obtained from otherwise healthy volunteers, and study the subsequent loss of this gene's function on the migratory capacity of these cells in the proposed in vitro experimental system. This concept has not yet been demonstrated in the literature, and if validated, would be a novel and fundamental description of the role of PAI-1 in human monocyte biology as related to the development of atherosclerosis.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Obese men and women

Criteria

Inclusion Criteria:

  • Ages 18 -50
  • No current or past medical problems

Exclusion Criteria:

  • Patients taking prescription drugs (hormonal birth control or herbal supplements may be taken.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00512369

Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Mohan Sathyamoorthy, MD Vanderbilt University
  More Information

No publications provided

Responsible Party: Douglas Vaughan, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00512369     History of Changes
Other Study ID Numbers: 060286, NIH
Study First Received: August 3, 2007
Last Updated: July 14, 2011
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Vanderbilt University:
Metabolic pathways
Atherosclerosis
Monocyte Function

Additional relevant MeSH terms:
Arteriosclerosis
Atherosclerosis
Arterial Occlusive Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 21, 2014